ABVC Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 116587 min ago

@ $1.300

Wydano: 8 vas. 2024 @ 20:07

Zwrot: 6.92%

Poprzedni sygnał: vas. 7 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: -7.80 %

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 20:13):

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States...

Stats
Dzisiejszy wolumen	1.53M
Średni wolumen	1.09M
Kapitalizacja rynkowa	14.68M
EPS	$0 ( 2024-03-29 )
Następna data zysków	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.570
ATR14	$0.00600 (0.43%)

Insider Trading

Date	Person	Action	type
2022-05-20	Jiang Shuling	Buy	Common Stock
2021-08-02	An Chihliang	Sell	Common Stock
2021-08-02	Sakamoto Norimi	Buy
2021-08-02	Odaira Yoshinobu	Sell	Common Stock
2021-08-02	Jiang Tsung Shann	Buy	Common Stock

INSIDER POWER
0.00
Last 77 transactions
Buy: 22 119 096 \| Sell: 9 170 000

Wolumen Korelacja

Długi: -0.11 (neutral)

Krótki: -0.07 (neutral)

Signal:(53.439) Neutral

AMERICAN BRIVISION Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

AMERICAN BRIVISION Korelacja - Waluta/Towar

-0.79
( moderate negative )

-0.70
( moderate negative )

0.00
( neutral )

-0.86
( strong negative )

0.73
( moderate )

AMERICAN BRIVISION Finanse

Annual	2023
Przychody:	$152 430
Zysk brutto:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2023
Przychody:	$152 430
Zysk brutto:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2022
Przychody:	$969 783
Zysk brutto:	$683 368 (70.47 %)
EPS:	$-5.15

FY	2021
Przychody:	$355 797
Zysk brutto:	$350 711 (98.57 %)
EPS:	$-0.510

Financial Reports:

No articles found.

AMERICAN BRIVISION

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.